USPTO Grants New Patent to Medifocus Inc. for New Heat Treatment System
Medifocus Inc.’s patent lawyers must be smiling all the way to the bank. The company has just won another patent in the US for its new heat treatment technology. The patent was granted by the USPTO on July 1st and this has increased Medifocus’ tally of patents in the US and internationally to over 100. All of Medifocus’ patents deal with the usage and method of using heat technology to treat diseases in the body.
Details of the New Patent
Medifocus’ new patent is titled “Apparatus and Method for Pre-Conditioning/Fixation and Treatment of Disease with Heat Activation/Release with Thermo activated Drugs and Gene Products.” The patent has been authored by the COO of the company, John Mon. In an interview Mon stated how this patent will allow the company to partner with other companies in the bio-tech field and collaborate with them to develop thermo activated/released drugs and gene products. The company hopes that this technology will bring about a new era in medicine and commercialize the use of targeted thermo activated/released drugs and gene products.
Medifocus has been developing and marketing minimally invasive treatment procedures that utilize focused heat treatment systems to cure diseases almost anywhere in the body. The heat treatment procedures that are developed by Medifocus can be used in the treatment of tumors – both cancerous and benign – enlarged prostate glands in men, and Benign Prostatic Hyperplasia (BPH) a non-cancerous enlargement of the prostate gland that affects half of all men above the age of 75. The company’s patent lawyers say that Medifocus has two technology platforms which enjoy comprehensive patent protection in the US as well as in the international market.
These are called as the “Endo-thermotherapy Platform” and the “Adaptive Phased Array Microwave Focusing Platform”. Using the technologies in these platforms, Medifocus has been developing therapeutic procedures and products for the international market. One of the products developed by the company, called the Prolieve(R) system, is used for the treatment of Benign Prostatic Hyperplasia (BPH), while the Adaptive Phased Array (APA) – 1000 system designed by the company has proved to be effective in the treatment of breast cancer in women.
A New Way of Treatment
Prolieve (R) has been approved by the Food and Drug Administration of USA (FDA) and is described as a device that uses endo-thermotherapy to cure prostate enlargement. The device heats the prostate while simultaneously dilating the prostatic urethra and the combine treatment offers both immediate and long term relief from the symptoms of BPH that men experience.
It is the only minimally invasive treatment available for BPH treatment that has shown effective results so far. The FDA has indicated that the Prolieve (R) system is akin to an “alternative to drug therapy” for treating BPH. When released into the market, the product has a potential to earn huge amounts of revenue for the company as there is an estimated $8 billion worth of non-surgical prescription drug therapy market in the US alone for the treatment of BPH.
The Private Sector comes through Again
The other product developed by the company is the APA-1000. Breast cancer is a known killer disease among women and the APA-1000 aims to combat it by using controlled microwaves to shrink the cancer tumors without causing any side effects to the surrounding breast tissue. Phase-III clinical trials have been started on the APA-1000 and if proved to be effective, the device can easily beat chemotherapy and surgical procedures that are traditionally used to treat breast cancer. Medifocus’ patent lawyers are awaiting successful completion of the Phase-III trials so that they can then get a commercial approval (PMA) for the product and launch it in the market.